AIMO, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 13.455
EU - Europa 10.328
AS - Asia 5.413
SA - Sud America 1.156
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 16
Totale 30.485
Nazione #
US - Stati Uniti d'America 12.876
RU - Federazione Russa 4.133
SG - Singapore 2.983
IT - Italia 2.092
GB - Regno Unito 1.286
BR - Brasile 1.031
DE - Germania 920
CN - Cina 796
HK - Hong Kong 736
CA - Canada 498
IE - Irlanda 424
UA - Ucraina 408
VN - Vietnam 263
FI - Finlandia 228
SE - Svezia 197
FR - Francia 154
NL - Olanda 117
IN - India 110
TR - Turchia 97
AT - Austria 84
PK - Pakistan 74
BD - Bangladesh 71
DK - Danimarca 64
ID - Indonesia 54
AR - Argentina 48
MX - Messico 46
PL - Polonia 45
ES - Italia 43
IQ - Iraq 38
AE - Emirati Arabi Uniti 32
ZA - Sudafrica 31
JP - Giappone 28
CH - Svizzera 23
LT - Lituania 22
UZ - Uzbekistan 22
MA - Marocco 21
BE - Belgio 20
VE - Venezuela 19
EC - Ecuador 17
EU - Europa 17
RO - Romania 17
CO - Colombia 15
CZ - Repubblica Ceca 15
IR - Iran 14
KE - Kenya 12
AU - Australia 11
EG - Egitto 11
SA - Arabia Saudita 11
AZ - Azerbaigian 9
JO - Giordania 9
TN - Tunisia 9
MC - Monaco 8
TW - Taiwan 7
AM - Armenia 6
CL - Cile 6
PA - Panama 6
PE - Perù 6
UY - Uruguay 6
DZ - Algeria 5
IL - Israele 5
KR - Corea 5
NI - Nicaragua 5
NP - Nepal 5
OM - Oman 5
PT - Portogallo 5
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
GE - Georgia 4
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
MY - Malesia 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
BB - Barbados 3
CI - Costa d'Avorio 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
LB - Libano 3
PH - Filippine 3
AO - Angola 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
MT - Malta 2
PS - Palestinian Territory 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
Totale 30.473
Città #
Singapore 1.775
Chicago 1.335
Los Angeles 711
Hong Kong 683
Salt Lake City 588
Chandler 562
Southend 543
Beijing 507
Fairfield 462
San Mateo 451
Moscow 433
Dublin 420
Ashburn 397
Woodbridge 359
Wilmington 350
Tampa 337
Houston 324
Cambridge 316
The Dalles 297
Buffalo 296
Seattle 273
Elk Grove Village 257
Portsmouth 242
Falls Church 237
Boardman 233
Munich 230
Stevenage 215
Ann Arbor 212
Ottawa 203
Milan 197
Beauharnois 193
Pisa 188
Jacksonville 179
Rome 175
Dearborn 156
Lawrence 155
Santa Clara 140
Florence 128
Dallas 127
Sterling 124
Lancaster 121
Dong Ket 117
New York 94
London 88
Nuremberg 88
Brooklyn 85
Frankfurt am Main 83
São Paulo 83
Helsinki 81
Miami 80
Dulles 76
Istanbul 70
Turku 65
San Diego 64
Lappeenranta 60
Detroit 50
Bologna 48
Kansas City 48
Washington 41
Phoenix 40
Fremont 38
Genoa 36
Palermo 36
Warsaw 36
Livorno 35
Vienna 35
Belo Horizonte 34
Central District 34
Lucca 34
Pittsburgh 34
Toronto 33
Naples 32
San Francisco 31
Boston 28
Rio de Janeiro 28
Düsseldorf 27
Assago 26
Redwood City 26
Amsterdam 25
Guangzhou 25
Las Vegas 23
Mexico City 23
Norwalk 23
Shanghai 23
Chennai 22
Hangzhou 22
Old Bridge 21
Charlotte 20
Montreal 20
Tashkent 20
Atlanta 19
Bari 19
Brasília 19
Brussels 19
Buti 19
Curitiba 19
Lauterbourg 19
Stockholm 19
Padova 18
Shenzhen 18
Totale 17.530
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.718
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.493
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.398
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 752
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 473
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 255
Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease 223
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 220
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? 217
Treating chemoreflex in heart failure: modulation or demolition? 214
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 214
Building medical knowledge from real world registries: The case of heart failure 213
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 206
Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure 196
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 194
Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance 191
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 188
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 187
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 180
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 178
The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia 176
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 174
A simple echocardiographic score to rule out cardiac amyloidosis 170
Cardiac light-chain deposition disease relapsing in the transplanted heart 166
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 164
Sex-related differences in chronic heart failure 161
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 159
"Targeting and Treating Apneas" in "The Breathless Heart: Apneas in Heart Failure" 158
Unmet needs in end-of-life care for heart failure patients 156
[The use of PROMs (patient-reported outcome measures) and PREMs (patient-reported experience measures) in Cardiology: current state and applications to improve patient care] 156
COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead 155
How to take arms against central apneas in heart failure 150
Position paper ANMCO: Impiego di vericiguat nello scompenso cardiaco: dalle evidenze al posizionamento terapeutico 148
Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms? 142
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 141
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 141
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 140
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 140
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 137
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 130
Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox 130
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 128
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 128
Cardiac troponins as biomarkers for cardiac disease 127
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 126
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction 125
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 124
Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis 124
Screening the health status of people working in a university 123
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 123
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 122
Amiodarone as a possible therapy for coronavirus infection 122
A simple echocardiographic score to rule out cardiac amyloidosis 120
Heart, kidney and FGF23: Les liaisons dangereuses 120
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure 119
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 119
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 117
Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart 117
Biomarkers for the diagnosis and management of heart failure 116
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 115
The Importance of Visceral Feedbacks: Focus on Chemoreceptors 115
Atrial amyloidosis: mechanisms and clinical manifestations 114
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 109
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 109
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 108
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 108
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 108
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 107
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis 107
Management of complications of cardiac amyloidosis: 10 questions and answers 105
Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction 105
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 104
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 104
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 104
Polymorphisms in the eNOS gene and the risk of coronary artery disease: Making the case for genome-wide association studies 103
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 103
Cardiovascular disease and COVID-19: les liaisons dangereuses 102
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 102
Subclinical cardiac damage in cancer patients before chemotherapy 102
Eligibility for vericiguat in a real‐world, contemporary heart failure population 101
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 101
Role of Imaging in Cardiomyopathies 100
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 100
The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) 100
Biomarkers for the diagnosis and management of heart failure: New frontiers 100
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 100
Sex-related differences in chronic heart failure 99
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 98
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 97
Molecular autopsy of sudden cardiac death in the genomics era 96
Left ventricular ejection fraction for risk stratification in chronic systolic heart failure 95
Therapies for cardiac light chain amyloidosis: An update 94
Wet is bad: Residual congestion predicts worse prognosis in acute heart failure 94
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 94
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 94
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 93
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 93
Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis 93
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease 93
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 92
Totale 18.465
Categoria #
all - tutte 222.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 222.834


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.357 195 209 96 208 108 321 143 129 217 158 252 321
2021/20222.538 177 295 65 231 108 145 298 491 203 285 52 188
2022/20231.732 162 165 75 154 210 208 42 155 341 43 121 56
2023/20241.762 107 49 336 122 75 154 106 71 88 96 95 463
2024/202519.303 220 243 878 362 665 803 1.951 3.264 1.352 2.531 4.186 2.848
2025/20261.094 1.094 0 0 0 0 0 0 0 0 0 0 0
Totale 30.862